FDA Oncology Announcements

Announcements Trials

Anti-RANKL × Plasma cell × Clear all

Conditions

Breast 1 Genitourinary 1 Plasma cell 1 Sarcoma 1

Drug Classes

Anti-CD38 20 Proteasome inhibitor 17 Immunomodulatory drugs (IMiDs) 14 Anti-BCMA-CD3 bispecific 4 Anti-BCMA ADC 3 XPO1 inhibitor 3 Anti-BCMA CAR T-cell 2 Anthracycline 1 Anti-GPRC5D-CD3 bispecific 1 Anti-RANKL 1 Anti-SLAMF7 1 CXCR4 inhibitor 1 HDAC inhibitor 1 Peptidase-enhanced nitrogen mustard 1

1 Announcement

Denosumab

Drug: Xgeva (denosumab) · Anti-RANKL antibody
Condition: Plasma cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡